| Name | Title | Contact Details |
|---|
Kovak Likly Communications is a Wilton, CT-based company in the Business Services sector.
Atlas Healthcare Partners is a company focused on the development, management, and investment in Ambulatory Surgery Centers (ASCs). Founded in 2018 and based in Phoenix, Arizona, it has quickly become one of the fastest-growing ASC management firms in the United States. The company aims to provide nonprofit health systems and physicians with effective alternatives to traditional ASC network development, emphasizing exceptional patient care and outcomes. Atlas offers a range of services to support its partners, including ASC development, management, and investment opportunities. The company collaborates with health systems to expand their ASC networks and provides operational expertise to ensure high-quality care. Additionally, Atlas serves as a strategic partner, helping health systems navigate their unique challenges and enhance patient experiences. Notable partnerships include collaborations with Banner Health and Corewell Health, among others. Atlas has been recognized as one of the Inc. 5000 Fastest Growing Private Companies in 2022 and 2023, reflecting its success in the ASC management sector.
The Stars Group Inc. is a Canadian gaming and online gambling company traded on Nasdaq and the Toronto Stock Exchange/ and headquartered in Toronto, Ontario, Canada.
Nidek Medical Products Inc is a Birmingham, AL-based company in the Business Services sector.
DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Over the course of three decades, we have been a trusted partner of royalty sellers and demonstrated strong execution, building a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world. That foundation sets us apart as we continue developing solutions for innovators while building and managing a risk-mitigated portfolio of therapeutic assets that generates attractive returns and growth potential for investors. We have deployed more than $2.5 billion, acquiring more than 70 royalties on 40-plus drugs.